ZIOPHARM Oncology Inc (ZIOP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ZIOPHARM Oncology Inc (ZIOP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3420
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ziopharm Oncology Inc (Ziopharm), formerly EasyWeb Inc, is a next-generation immune therapies provider. The company offers controlled IL-12 and t-cell therapy. Its next-generation immune therapie platform provides turning cold tumors hot by activating an immune response and non viral genetic modification of CART-T cells and TCRs. Ziopharm develops novel gene expression, control and cell technologies to provide cell-based therapies for the treatment of cancer and graft-versus-host-disease. The company provides cancer care services for solid tumors, brain cancer, pediatric cancer, and blood cancer. Its products and technologies are used in the treatment of hematologic malignancies, solid tumors and graft-versus-host-disease. Ziopharm is headquartered in Boston, Massachusetts, the US.

ZIOPHARM Oncology Inc (ZIOP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
ZIOPHARM, Intrexon Enter into Agreement with NCI 11
Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 12
Ziopharm Expands Co-Development Agreement with Intrexon 13
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 14
Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 16
Licensing Agreements 17
Predictive Therapeutics Enters into Licensing Agreement with ZIOPHARM Oncology 17
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 18
Equity Offering 20
ZIOPHARM Oncology Prices Private Placement of Shares for USD50 Million 20
Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 21
Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million 22
ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million 23
ZIOPHARM Oncology Inc – Key Competitors 25
ZIOPHARM Oncology Inc – Key Employees 26
ZIOPHARM Oncology Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 08, 2018: Ziopharm Oncology reports second quarter 2018 financial results and provides corporate update 28
May 10, 2018: Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update 32
Mar 01, 2018: Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 34
Nov 06, 2017: ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities 36
Jul 31, 2017: ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities 39
May 01, 2017: Ziopharm Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities 42
Feb 16, 2017: ZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on Recent Activities 45
Corporate Communications 47
Aug 07, 2018: Ziopharm Oncology announces changes to its board of directors 47
Sep 28, 2017: ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer 48
Product News 49
Oct 23, 2017: A Virus, a Gene and a Pill Used to Harness the Immune System to Fight Brain Tumor in Children 49
09/01/2017: ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit 50
Clinical Trials 51
Jun 18, 2018: Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy 51
May 02, 2017: ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia 52
Jan 31, 2017: ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing “Point-of-Care” Approach 53
Other Significant Developments 54
Feb 06, 2018: Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ZIOPHARM Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ZIOPHARM, Intrexon Enter into Agreement with NCI 11
Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 12
Ziopharm Expands Co-Development Agreement with Intrexon 13
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 14
Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 16
Predictive Therapeutics Enters into Licensing Agreement with ZIOPHARM Oncology 17
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 18
ZIOPHARM Oncology Prices Private Placement of Shares for USD50 Million 20
Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 21
Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million 22
ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million 23
ZIOPHARM Oncology Inc, Key Competitors 25
ZIOPHARM Oncology Inc, Key Employees 26
ZIOPHARM Oncology Inc, Subsidiaries 27

List of Figures
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ZIOPHARM Oncology Inc (ZIOP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Oncology Venture ApS-製薬・医療分野:企業M&A・提携分析
    Summary Oncology Venture ApS (Oncology Venture), a subsidiary of Oncology Venture Sweden AB is a drug development company that discovers new oncology products, and rescuing failed ones. The company provides gene-tumor-technology for identifying patients with resistance to anticancer drug. Its activi …
  • Municipal Energy Agency of Nebraska:企業の戦略的SWOT分析
    Municipal Energy Agency of Nebraska - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Cesca Therapeutics Inc (KOOL):製品パイプライン分析
    Summary Cesca Therapeutics Inc (Cesca) researches, develops, and commercializes cell based therapeutics for applications in regenerative medicine. Its proprietary technology platform, PXP is used to develop autologous cell-based therapies for the in the vascular and orthopedic markets. Its device di …
  • Lanxess AG:企業の戦略・SWOT・財務情報
    Lanxess AG - Strategy, SWOT and Corporate Finance Report Summary Lanxess AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Laboratories Ojer Pharma SL:製薬・医療:M&Aディール及び事業提携情報
    Summary Laboratories Ojer Pharma SL (Ojer Pharma) is a developer of pharmaceutical products in dermatology. The company's products categories include prescription medicine, over the counter OTC, medical devices and cosmetic products. It offers products such as previderm, dermatul nasal, dermatul lip …
  • Hanwha Corp (000880):企業の財務・戦略的SWOT分析
    Hanwha Corp (000880) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Macy’s Inc:戦略・SWOT・企業財務分析
    Macy's Inc - Strategy, SWOT and Corporate Finance Report Summary Macy's Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Epiroc AB (EPI A):企業の財務・戦略的SWOT分析
    Epiroc AB (EPI A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Ono Pharmaceutical Co Ltd (4528):医療機器:M&Aディール及び事業提携情報
    Summary Ono Pharmaceutical Co Ltd (Ono Pharmaceutical) is a focuses on the research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes pharmaceuticals for the treatment of type II diabetes, overactive bladder, osteoporosis, Alzh …
  • Anhui Construction Engineering Group Co., Ltd.:企業の戦略・SWOT・財務情報
    Anhui Construction Engineering Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Anhui Construction Engineering Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Cytodyn Inc (CYDY):企業の財務・戦略的SWOT分析
    Summary Cytodyn Inc (Cytodyn) is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment of Human Immunodeficiency Virus (HIV) infections. Its pipeline products include Leronlimab (PRO 140), a ful …
  • VTB Bank:企業の戦略・SWOT・財務情報
    VTB Bank - Strategy, SWOT and Corporate Finance Report Summary VTB Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Laboratory Corp of America Holdings (LH)-製薬・医療分野:企業M&A・提携分析
    Summary Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a wide range of diagnostic technologies and testing services. The company offers clinical diagnostics la …
  • Alliance Data Systems Corp (ADS):企業の財務・戦略的SWOT分析
    Alliance Data Systems Corp (ADS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Corium International Inc (CORI):製薬・医療:M&Aディール及び事業提携情報
    Summary Corium International Inc (Corium) is a commercial-stage biopharmaceutical company that produces and develops central nervous system pharmaceutical products. The company develops transdermal healthcare products with the help of Corplex technology platform using small molecules. Its products i …
  • Aerojet Rocketdyne Holdings Inc:企業の戦略・SWOT・財務情報
    Aerojet Rocketdyne Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Aerojet Rocketdyne Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Suzhou Xinrong Best Medical Instrument Co Ltd-医療機器分野:企業M&A・提携分析
    Summary Suzhou Xinrong Best Medical Instrument Co Ltd (Suzhou Xinrong) is a medical device company that manufactures orthopedic medical instruments. The company prvides products such as medullary cavity plug, acetabular screws, metal ball head, stem and titanium plate anterior thoracolumbar fixed eq …
  • Surgical Specialties Corp:企業の戦略・SWOT・財務分析
    Surgical Specialties Corp - Strategy, SWOT and Corporate Finance Report Summary Surgical Specialties Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Angelini Group:企業の戦略的SWOT分析
    Angelini Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • China Aviation Oil (Singapore) Corp Ltd (G92)
    China Aviation Oil (Singapore) Corp Ltd (G92) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company

◆H&Iグローバルリサーチ株式会社のお客様(例)◆